

JOIN US IN PERSON for an engaging discussion about head-to-head results you should know for preventive migraine management

PRESENTED BY:



Roger Chapman, NP

Advanced Practice Nurse Practitioner
Precision Spine Care, Headache Division
Tyler TX

**Tuesday, January 13, 2026
at 6:15 PM CT**

III Palms

**6361 Old Jacksonville Highway, Tyler, TX
75703-0573**



Please RSVP using the link or QR code:
<https://migrainelive.com/register/236252>
Contact your AbbVie Representative with questions
Dustin Jones
Phone: 9035302125 Email:
dustin.jones@abbvie.com

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

Hypertension (HTN): Development or worsening of pre-existing HTN has been reported following the use of CGRP antagonists, including QULIPTA. Some patients who developed new-onset HTN had risk factors. There were cases requiring initiation of HTN treatment and, in some cases, hospitalization. HTN may occur at any time but was most frequently reported within 7 days of initiation. QULIPTA was discontinued in many of the cases. Monitor patients for new-onset or worsening of pre-existing HTN, and consider whether discontinuation of QULIPTA is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud's phenomenon (RP): Development, recurrence, or worsening of pre-existing RP has been reported following the use of CGRP antagonists, including QULIPTA. In cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms. QULIPTA should be discontinued if signs or symptoms of RP develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of RP should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

Please see accompanying full Prescribing Information or visit
https://www.rxabbvie.com/pdf/qulipta_pi.pdf.

1. Charles AC, et al. *Headache*. 2024;64(4):333-341.

This promotional event is brought to you by AbbVie and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s). The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.